A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Amid a crackdown on manufacturers selling unsafe food products, the Food Safety and Standards Authority of India (FSSAI) has now turned its attention to food claims such as “immunity booster” and “nutrient-rich” endorsed by celebrities and social media influencers.

FSSAI Asks Influencers To Verify Food Claims

With millions of followers, celebrities and digital creators have become an increasingly popular channel for brands marketing health drinks, protein supplements, snacks and packaged foods.

“When you say ‘boosts immunity’, ‘rich in nutrients’, consumers trust you. Make sure every claim deserves that trust,” FSSAI said.

The food regulator asked influencers to verify that every claim made by a brand is:

• Truthful
• Scientifically substantiated
• Compliant with food safety regulations

FSSAI warned that misleading food advertisements and endorsements can have legal consequences.

Under the Food Safety and Standards Act, 2006, and the Food Safety and Standards (Advertising and Claims) Regulations, 2018, misleading food advertisements and endorsements are prohibited and may attract legal action and penalties.

Also read: Why Indian Doctors Are Seeking A Ban On Junk Food Ads And Mandatory Warning Labels On Packaging?

FSSAI Steps Up Food Safety

In recent weeks, FSSAI has acted against or scrutinized products and companies over misleading claims, hygiene and food-safety violations, non-compliant ingredients, labelling issues and failure to meet prescribed standards.

The action has covered packaged foods, liquor, edible oils, sweeteners and high-caffeine beverages. The latest move involves tightening packaging rules for pan masala.

New Pan Masala Packaging Rules

Under the new Food Safety and Standards (Packaging) Amendment Regulations, 2026, notified on August 10, pan masala packaging can no longer use plastic-based materials, plastic laminates, aluminium foil or metallised layers.

Pan masala can now be packaged in materials made of paper, paperboard, cellulose and other naturally derived materials, provided they are completely free from plastic and synthetic polymers. Tin and glass containers are also allowed.

The decision follows an earlier draft notification issued by FSSAI in April, which proposed adding specific packaging materials for pan masala to the food packaging regulations.

Why Is FSSAI Targeting Pan Masala Packaging?

Read More: World Organ Donation Day 2026: Too Old Or Too Sick To Donate Organs? Doctors Bust Key Myths

Pan masala sachets have traditionally relied heavily on plastic and foil materials as they are lightweight, inexpensive and shield the contents from moisture.

However, such multilayer plastic packaging is difficult to recycle and contributes to persistent plastic waste. The new rules push manufacturers towards packaging made of paper and other naturally derived materials that will not harm the environment.

This does not mean that pan masala itself is safer to consume. Pan masala, particularly products containing tobacco or areca nut, continues to be harmful. The regulation is primarily about packaging standards and waste.

Taiwan’s Food and Drug Administration (TFDA) has recalled of 87,360 tablets of a blood pressure medication after a specific batch failed a quality test. Health officials raised concerns, saying that the drug may not work as effectively as expected.

The recall involves Beniel F.C. Tablets 8 mg, manufactured by Synmosa Biopharma Corp. The affected batch is 2KA31, and the medicine contains benidipine hydrochloride, a drug used to treat high blood pressure.

Why Has The Blood Pressure Medicine Been Recalled?

The problem was first identified during a stability test of the drug, which found that the tablets failed to meet the required dissolution standards.

In simple terms, a dissolution test is conducted to check how a tablet breaks down and releases its active ingredient under controlled conditions.

This is an important test as a tablet has to release the medicine in the proper way for the body to absorb it and for the drug to produce its intended effect.

Also read: Blood Pressure, Heart Medicines May Boost Effectiveness Of Antidepressants, AIIMS Study Finds

What Is Benidipine And How Does It Work?

Benidipine hydrochloride belongs to a group of drugs called calcium channel blockers. These medicines help lower blood pressure by relaxing and widening blood vessels. This enables the blood to flow more easily and reduces the pressure against artery walls.

That is why a problem affecting how a tablet dissolves can matter. If the active ingredient is not released into the body as expected, the medicine may not deliver its intended therapeutic effect.

Also read: Why Are More Women Under 35 Reporting Heart-Related Symptoms?

Is There A Risk Of Medicine Shortage?

According to the TFDA, there is no immediate concern of medication shortage. Other batches of Beniel F.C. Tablets 8 mg are not affected, and the manufacturer has sufficient inventory.

Production of the drug will also not been stopped. Taiwan News reported that two other products containing the same active ingredient are also authorised for sale.

The manufacturer has been ordered to complete the recall by August 24 and submit an investigation report along with corrective and preventive measures for future production.

Also read: Smoking, Diabetes, High Blood Pressure May Fuel the Most Dangerous Type of Artery Plaque, Study Finds

What Should Patients Taking Medicine From Recalled Batch Do?

Patients should not stop their blood pressure medication on their own. The TFDA advised people who are concerned about their prescription to speak with their doctor about whether an alternative medicine is necessary.

The recall highlights an often overlooked part of medication safety: a medicine can contain the correct active ingredient but still fail a quality test if its physical properties affect how the drug is released. For now, the concern is focused on one specific batch, rather than the entire Beniel F.C. product line.

The ongoing Ebola virus disease epidemic in the Democratic Republic of Congo (DRC) is moving faster than any previous outbreak, said WHO chief Dr Tedros Adhanom Ghebreyesus.

According to official data, confirmed cases have reached 4,449, with the death toll climbing to 2,061 across five provinces and 53 health zones in the country. However, the number of uncounted cases may be far higher than the reported figure.

“It is already the second-biggest Ebola epidemic on record, and it is moving faster than any previous Ebola outbreak. At its current pace, it is on track to eclipse the West African Ebola outbreak of 2014 to 2016,” Tedros said in a briefing.

The 2014-2016 outbreak reported at least 28,000 cases and took about eight months to reach 1,000 deaths.

Ebola 2026: Big Head Start, Likely to Peak in 6 Months

Tedros noted that the current “outbreak had a big head start, it is still way ahead of us, and we are playing catch-up.”

He said this even as reports showed that the disease caused by the rare Bundibugyo virus had been circulating since February and went undetected for months. The WHO declared the outbreak on May 15.

Dr Abdirahman Mahamud, WHO’s director for health emergency alert and response operations, said the agency expects the outbreak to reach its peak within six months, AP News reported.

“But ... that’s the moderate scenario,” Mahamud said. “There is a one-case scenario where this outbreak may last nine months to 12 months.”

Also read: Ebola Death Toll Tops 2,000 In DRC: New Study Reveals Likely Source Of Bundibugyo Virus Outbreak

Unknown Chains of Transmission

Tedros said about 90% of all cases and 80% of deaths are in the province of Ituri, with sustained transmission in the towns of Bunia, Rwampara, Nizi and Lita.

“Most concerningly, we see a high proportion of deaths in communities instead of treatment units, outside of known contact lists,” Tedros said.

“That tells us there are chains of transmission we don’t know about, and until we know about – and break – every chain of transmission, we will not stop the outbreak.”

Most transmission happens when people have late-stage disease and are not in treatment, or when their bodies are handled after death.

Early clinical care and safe and dignified burials are therefore critical for interrupting transmission. Both depend on the trust of affected communities, making community engagement and ownership essential.

“There is no other way,” Tedros said, adding that the response is now being scaled up, with the primary goal of interrupting transmission.

With partners, WHO is mapping and pooling resources to strengthen community-based surveillance, bring every suspected case into care and reach the 95% contact-tracing target needed to interrupt transmission. Currently, the rate is around 80%.

Read More: Ebola Outbreak: Officials To Probe Whether Bundibugyo Virus Is Mutating

Progress Made

• More than 21,000 community health workers have been trained.
• Treatment centres, safe burial teams, laboratories and community engagement teams are operating across the affected provinces, reaching hundreds of thousands of people.
• A total of 886 patients have recovered, even without specific therapeutics and vaccines, which are progressing through trials.
• For the first time, two vaccines specifically designed against Bundibugyo virus have entered Phase 1 safety trials in humans.
• Two new animal studies of a vaccine against Zaire ebolavirus — the more common species — have shown promising evidence of cross-protection in animals, Tedros said.